Goldline Pharmaceutical Ltd
Goldline Pharmaceutical Ltd (GLPL) last reported results for the quarter ended Mar 2026, with sales of ₹17.31 crore and net profit of ₹2.76 crore. The stock last traded at ₹31.1, a market capitalisation of ₹29.9 crore, on a P/E of 7.26. Over the past 52 weeks the stock has ranged between ₹28.5 and ₹60. Figures are as of 6 Oct 2026 and are not real time.
Goldline Pharmaceutical Ltd share price and key metrics
- Current price
- ₹31.1
- Market cap
- ₹29.9 cr
- Stock P/E
- 7.26
- ROE
- 39.4%
- ROCE
- 30.6%
- Dividend yield
- 0.00%
- 52w high / low
- 60.0/28.5
Metrics as of 6 Oct 2026. Not real time.
Track Goldline Pharmaceutical Ltd
Cruxal reads every Goldline Pharmaceutical Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Goldline Pharmaceutical Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 16%
- TTM
- 11%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 119%
- TTM
- 42%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- 1 Year
- %
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 39%
- Last Year
- 39%
Goldline Pharmaceutical Ltd quarterly results
| ₹ crore | Sep 2025 | Mar 2026 |
|---|---|---|
| Sales | 13.89 | 17.31 |
| Expenses | 11.25 | 13 |
| Operating profit | 2.64 | 4.31 |
| OPM % | 19.01% | 24.90% |
| Other income | 0 | 0 |
| Interest | 0.67 | 0.65 |
| Depreciation | 0.12 | 0.12 |
| Profit before tax | 1.85 | 3.54 |
| Tax % | 26.49% | 21.75% |
| Net profit | 1.36 | 2.76 |
| EPS (₹) | 1.97 | 4.00 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Goldline Pharmaceutical Ltd annual results
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 19.73 | 23.48 | 28.01 | 31.18 |
| Operating profit | 2.41 | 4.34 | 6.15 | 7.09 |
| OPM % | 12.21% | 18.48% | 21.96% | 22.74% |
| Net profit | 0.26 | 1.81 | 2.83 | 4.12 |
| EPS (₹) | 1.30 | 7.87 | 4.10 | 5.97 |
TTM is the trailing twelve months to the most recent quarter.
Goldline Pharmaceutical Ltd balance sheet
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity capital | 2.00 | 2.30 | 6.90 | 6.90 |
| Reserves | 2.08 | 3.76 | 1.55 | 5.54 |
| Borrowings | 12.64 | 12.94 | 12.85 | 10.97 |
| Other liabilities | 2.67 | 3.93 | 4.88 | 5.47 |
| Total liabilities | 19.39 | 22.93 | 26.18 | 28.88 |
| Fixed assets | 2.50 | 2.95 | 2.89 | 2.71 |
| CWIP | 0.00 | 0.45 | 0.00 | 0.00 |
| Investments | 0.07 | 0.03 | 0.03 | 0.03 |
| Other assets | 16.82 | 19.50 | 23.26 | 26.14 |
| Total assets | 19.39 | 22.93 | 26.18 | 28.88 |
As reported by the company. Total assets equal total liabilities by construction.
Goldline Pharmaceutical Ltd cash flow
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Cash from operations | 2.39 | 2.92 | 3.18 | 2.81 |
| Cash from investing | -1.04 | -1.11 | 0.16 | -0.06 |
| Cash from financing | -1.44 | -1.08 | -2.89 | -3.40 |
| Net cash flow | -0.09 | 0.74 | 0.45 | -0.65 |
| Free cash flow | 1.38 | 1.81 | 3.35 | 2.75 |
| CFO / operating profit | 101% | 72% | 66% | 53% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Goldline Pharmaceutical Ltd operating ratios
| Per year | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| ROCE % | — | 23.40% | 29.28% | 30.64% |
| Debtor days | 159.65 | 149.54 | 139.30 | 188.82 |
| Inventory days | 336.20 | 450.39 | 229.14 | 202.38 |
| Days payable | 54.47 | 98.62 | 69.62 | 60.29 |
| Cash conversion cycle | 441.39 | 501.32 | 298.82 | 330.91 |
| Working capital days | 143.74 | 132.76 | 133.57 | 156.28 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Goldline Pharmaceutical Ltd shareholding pattern
| % held | May 2026 |
|---|---|
| Promoters | 57.29% |
| FIIs | 5.16% |
| DIIs | 7.81% |
| Public | 29.74% |
| No. of shareholders | 271 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Goldline Pharmaceutical Ltd corporate filings
- Intimation of Closure of Trading windowInsider Trading / SASTlow impact
- Goldline Pharmaceutical Limited Promoter Increases Stake by 0.62% via Open Market PurchaseInsider Trading / SASTmedium impact
Cruxal's analysis: Goldline Pharmaceutical Limited has disclosed that its Managing Director and Promoter…
Read the full analysis - Goldline Pharmaceutical Limited: Promoter Amol Laxmikant Mujumdar Increases Stake by 0.19% via Open Market PurchaseInsider Trading / SASTmedium impact
Cruxal's analysis: Goldline Pharmaceutical Limited has disclosed that its Managing Director and Promoter…
Read the full analysis - Goldline Pharmaceutical Limited: Promoter Increases Stake by 0.62% via Open Market PurchaseInsider Trading / SASTmedium impact
Cruxal's analysis: Goldline Pharmaceutical Limited has disclosed that its Managing Director and Promoter…
Read the full analysis - Goldline Pharmaceutical Limited Announces Successful Passing of All Resolutions at 22nd Annual General MeetingAGM/EGMlow impact
Cruxal's analysis: Goldline Pharmaceutical Limited has successfully concluded its 22nd Annual General…
Read the full analysis - Goldline Pharmaceutical Limited Reports Strong FY 2025-26 Financial Growth at 22nd AGMAGM/EGMhigh impact
Cruxal's analysis: Goldline Pharmaceutical Limited announced robust financial performance for FY 2025-26…
Read the full analysis - Goldline Pharmaceutical Limited Promoter Increases Stake to 30.08% via Open Market PurchaseInsider Trading / SASTmedium impact
Cruxal's analysis: Goldline Pharmaceutical Limited promoter and Whole Time Director, Mr. Swapan Khandelwal…
Read the full analysis - Goldline Pharmaceutical Limited Promoter Increases Stake to 30.08% via Open Market PurchaseInsider Trading / SASTmedium impact
Cruxal's analysis: Goldline Pharmaceutical Limited has disclosed that Mr. Swapan Khandelwal, Promoter and…
Read the full analysis - Goldline Pharmaceutical Limited announces 22nd Annual General Meeting (AGM) and e-voting scheduleCompany Updatelow impact
Cruxal's analysis: Goldline Pharmaceutical Limited has issued a formal notice regarding its 22nd Annual…
Read the full analysis - Goldline Pharmaceutical Ltd announces record date for remote e-votingCorp. Actionlow impact
Cruxal's analysis: Goldline Pharmaceutical Ltd has issued an intimation regarding the record date for remote…
Read the full analysis - Goldline Pharmaceutical Ltd schedules 22nd Annual General Meeting for August 29, 2026Corp. Actionlow impact
Cruxal's analysis: Goldline Pharmaceutical Ltd has announced the closure of its register of members from…
Read the full analysis - Goldline Pharmaceutical Ltd submits Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Goldline Pharmaceutical Ltd has filed its Annual Report for the financial year 2025-26 as…
Read the full analysis - Goldline Pharmaceutical Limited Announces 22nd AGM with Proposals for Related Party Transactions and Director Loan ConvertibilityAGM/EGMmedium impact
Cruxal's analysis: Goldline Pharmaceutical Limited has scheduled its 22nd Annual General Meeting for August…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.